ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

New IGL-2 Perfusate in Liver HOPE Strategies

A. Panisello-Rosello1, C. Castro-Benítez2, E. Folch-Puy1, J. Rosello-Catafau1, R. Adam2

1Experimental Pathology, Instituto de Investigaciones Biomedicas de Barcelona, Barcelona, Spain, 2Centre Hépato-Billiare, Hôpital Paul Brousse, Paris, France

Meeting: 2020 American Transplant Congress

Abstract number: D-281

Keywords: Graft survival, Ischemia, Liver grafts, Preservation

Session Information

Session Name: Poster Session D: Ischemia Reperfusion & Organ Rehabilitation

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: HOPE has shown to optimize graft liver preservation. However, the most used perfusion solutions as such as Belzer-MPS and its generics were initially for kidney purposes and given its composition, may not be the most suitable for the liver. The aim of this study is to compared Belzer-MPS generic (Perf-gen) with an IGL-2 solution (a modified IGL-1 solution enriched with increased PEG35 and glutathione contents) for HOPE purposes.

*Methods: Livers from Sprague Dawley rats were extracted and preserved either in IGL-2 or PerfGen solution (7 hours; 4ºC), followed by HOPE (1 hour at 4 ºC) and then normothermic reperfusion (1 hour at 37ºC). After organ recovery, liver injury mitochondrial damage (GLDH) and Aldehyde Dehydrogenase-2 (ALDH2) activity were measured.

*Results: Liver injury (measured as ATL/AST) and mitochondrial damage (measured as GLDH) levels, shows a significant decrease during HOPE phase. Mitochondrial ALDH2 activity is enhanced in the IGL-2 group when compared to Perf-gen.

*Conclusions: IGL-2 perfusate improved liver graft preservation when compared with Perf-gen during HOPE through mitochondrial protection.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Panisello-Rosello A, Castro-Benítez C, Folch-Puy E, Rosello-Catafau J, Adam R. New IGL-2 Perfusate in Liver HOPE Strategies [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/new-igl-2-perfusate-in-liver-hope-strategies/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences